ALS drug will be pulled from US market after study showed patients didn't benefit

  • 📰 KPRC2
  • ⏱ Reading Time:
  • 32 sec. here
  • 4 min. at publisher
  • 📊 Quality Score:
  • News: 23%
  • Publisher: 68%

Health ニュース

Washington News,Business

The maker of a drug for Lou Gehrig’s disease that recently failed in a study says it will pull the medicine from the U.S. market.

ASK 2: What should you do when a driver comes to an intersection with a flashing yellow left turn arrow?Business

Amylyx Pharmaceuticals announced it will voluntarily halt sales and marketing of the drug in the U.S. and Canada, where new patients will no longer be able to get a prescription.“While this is a difficult moment for the ALS community, we reached this path forward in partnership with the stakeholders who will be impacted and in line with our steadfast commitment to people living with ALS," company executives said in a statement.

Relyvrio is a powder that combines two older drugs: a prescription medication for liver disorders and a dietary supplement associated with traditional Chinese medicine.

このニュースをすぐに読めるように要約しました。ニュースに興味がある場合は、ここで全文を読むことができます。 続きを読む:

 /  🏆 80. in JP
 

コメントありがとうございます。コメントは審査後に公開されます。

日本 最新ニュース, 日本 見出し